NP Victoria Garcia-Albea discusses highlights from her ELEVATE-ing the Science: A Review of Abstract Submissions at the 2nd Annual Elevate-Derm Alliance Summer Conference in Park City, Utah, at the Grand Hyatt Deer Valley.
In this video
In conversation with Lisa Weiss, Garcia-Albea makes the case for poster sessions: they give early-career clinicians a way to get their information out there when they haven't yet been invited to give a talk, they carry study data that doesn't fit a lecture format, and they create a chance to interact with pharma and sponsors and see what's new in their research.
Turning to atopic dermatitis, she notes dupilumab is still well represented but flags growing interest in lebrikizumab, with new three-year posters showing safety and efficacy out to three years. She points to topical monotherapy data offering long medication-free stretches — up to two and a half months — and to a first-ever oral IL-23, which she finds especially promising since patients often prefer pills over injections. She also highlights the value of phase four data, the longer-term safety and efficacy that emerges after medications have been on the market, information providers aren't always aware of.
- Poster sessions surface data that doesn't fit a lecture and give early-career clinicians a platform to share their work.
- New three-year posters on lebrikizumab demonstrate sustained safety and efficacy in AD.
- Topical monotherapy can now provide long medication-free periods — up to about two and a half months.
- An oral IL-23 is coming for the first time, an option patients may prefer over injections.
- Phase four data offers the longer-term safety and efficacy picture that emerges once medications have been in use for a while.
